510 Participants Needed

OP-1250 for Advanced Breast Cancer

(OPERA-01 Trial)

Recruiting at 152 trial locations
OP
Overseen ByOlema Pharmaceuticals, Inc.
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Olema Pharmaceuticals, Inc.
Must be taking: GnRH agonist
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants must have previously received a CDK4/6 inhibitor with endocrine therapy, so you might need to continue certain treatments. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug OP-1250 (Palazestrant) for advanced breast cancer?

Research shows that letrozole, a component of the treatment, is effective in treating advanced breast cancer, with studies indicating it is more effective than tamoxifen and anastrozole in certain cases. Letrozole has been shown to improve disease-free survival and has a higher overall response rate compared to anastrozole in advanced breast cancer.12345

What safety data exists for OP-1250 and related treatments in humans?

Letrozole and anastrozole, which are similar to OP-1250, have been used safely in postmenopausal women with breast cancer. Common mild side effects include hot flashes, joint pain, nausea, fatigue, and headaches.12678

What makes OP-1250 (Palazestrant) unique compared to other breast cancer drugs?

OP-1250 (Palazestrant) is unique because it is a new type of drug being tested for advanced breast cancer, potentially offering a different mechanism of action compared to existing aromatase inhibitors like anastrozole, exemestane, and letrozole, which are already used for hormone receptor-positive breast cancer.268910

What is the purpose of this trial?

This trial is testing a new drug called palazestrant to see if it works better than current treatments for adults with advanced breast cancer that has not responded to previous therapies. The drug aims to stop cancer growth by blocking estrogen.

Research Team

MD

Medical Director, MD

Principal Investigator

Olema Pharmaceuticals, Inc.

Eligibility Criteria

This trial is for adults with ER+/HER2- advanced breast cancer that's progressed after endocrine therapy and a CDK4/6 inhibitor. Participants need to be in good physical condition (ECOG 0 or 1), have proper organ function, and if male or pre-menopausal female, agree to take hormone-blocking injections.

Inclusion Criteria

I am an adult.
My cancer can be measured or is only in my bones.
I've been treated with a CDK4/6 inhibitor and hormone therapy for advanced cancer.
See 5 more

Exclusion Criteria

My cancer is causing symptoms or organ failure, making me ineligible for hormone therapy.
I need urgent treatment for cancer spread to my brain or spinal cord.
I have no major health issues that could affect my treatment.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose-Selection

Participants are randomized to one of the two doses of palazestrant or to the standard-of-care endocrine therapy to evaluate adverse events, drug discontinuation, and dose reduction

16 weeks

Treatment

Participants receive either palazestrant or standard-of-care endocrine therapy to compare overall survival and progression-free survival

Up to 4 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years

Treatment Details

Interventions

  • Anastrozole
  • Exemestane
  • Fulvestrant
  • Letrozole
  • OP-1250 (Palazestrant)
Trial Overview The study compares OP-1250, a new treatment option, against standard treatments like fulvestrant or aromatase inhibitors (Anastrozole, Letrozole, Exemestane) in patients whose breast cancer has worsened despite previous therapies.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Palazestrant (OP-1250)Experimental Treatment1 Intervention
Participants will receive Palazestrant
Group II: Standard of Care Endocrine TherapyActive Control4 Interventions
Participants will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)

Anastrozole is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Arimidex for:
  • Breast cancer
  • Early breast cancer in postmenopausal women
🇺🇸
Approved in United States as Arimidex for:
  • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
  • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer
🇨🇦
Approved in Canada as Arimidex for:
  • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
  • Treatment of postmenopausal women with hormone receptor-positive advanced breast cancer
🇯🇵
Approved in Japan as Arimidex for:
  • Breast cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Olema Pharmaceuticals, Inc.

Lead Sponsor

Trials
5
Recruited
970+

Findings from Research

Letrozole is an effective treatment for postmenopausal women with early-stage or advanced hormone-sensitive breast cancer, showing a 43% reduction in disease recurrences when used as extended adjuvant therapy beyond standard tamoxifen treatment.
In advanced breast cancer, letrozole outperformed tamoxifen in terms of time to disease progression (9.4 months vs. 6.0 months) and has a similar tolerability profile, making it a recommended first-line therapy according to treatment guidelines.
Letrozole: a review of its use in postmenopausal women with breast cancer.Simpson, D., Curran, MP., Perry, CM.[2018]
The FACE trial is a large-scale study involving 4000 postmenopausal women with hormone receptor-positive, node-positive breast cancer, comparing the efficacy and safety of letrozole and anastrozole over a treatment period of up to 5 years.
The primary goal of the trial is to assess disease-free survival (DFS), while secondary objectives include evaluating overall survival (OS) and the time to distant metastases, which will provide comprehensive insights into the effectiveness of both treatments.
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?Jonat, W., Mundhenke, C.[2018]
In a study involving 713 postmenopausal women with advanced breast cancer, letrozole (2.5 mg/day) demonstrated a significantly higher overall response rate (19.1%) compared to anastrozole (1 mg/day) (12.3%), indicating that letrozole may be more effective as a second-line endocrine therapy.
Despite the improved response rate with letrozole, both treatments showed no difference in time to progression, overall survival, or safety profiles, suggesting that while letrozole is more effective in eliciting responses, both drugs are well tolerated and have similar safety outcomes.
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.Rose, C., Vtoraya, O., Pluzanska, A., et al.[2022]

References

Letrozole: a review of its use in postmenopausal women with breast cancer. [2018]
The FACE trial: letrozole or anastrozole as initial adjuvant therapy? [2018]
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). [2022]
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. [2022]
Letrozole as primary medical therapy for locally advanced and large operable breast cancer. [2022]
New aromatase inhibitors for breast cancer. [2019]
[Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer]. [2018]
New developments in the treatment of postmenopausal breast cancer. [2018]
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. [2019]
10.United Statespubmed.ncbi.nlm.nih.gov
Nonsteroidal and steroidal aromatase inhibitors in breast cancer. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security